We additionally found that PLOD2 promoted the release of ECM-degrading MMP2—a mechanism associated with enhanced invasiveness and worse outcomes in different types of cancer, including glioma [33,34,35]. This evidence concerns the gene MMP2 and central nervous system cancer.